Free Trial

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences logo
$123.11 +0.30 (+0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$123.45 +0.34 (+0.28%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
6
Buy
22

Based on 28 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 6 have given a hold rating, 20 have given a buy rating, and 2 have given a strong buy rating for GILD.

Consensus Price Target

$120.04
-2.49% Downside
According to the 28 analysts' twelve-month price targets for Gilead Sciences, the average price target is $120.04. The highest price target for GILD is $145.00, while the lowest price target for GILD is $95.00. The average price target represents a forecasted downside of -2.49% from the current price of $123.11.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

TypeCurrent Forecast
10/20/24 to 10/20/25
1 Month Ago
9/20/24 to 9/20/25
3 Months Ago
7/22/24 to 7/22/25
1 Year Ago
10/21/23 to 10/20/24
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
20 Buy rating(s)
19 Buy rating(s)
14 Buy rating(s)
10 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
9 Hold rating(s)
10 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$120.04$117.17$111.38$86.37
Forecasted Upside-2.49% Downside2.70% Upside1.10% Upside-0.41% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-2.49% Downside1,436.04% Upside12.66% Upside
News Sentiment Rating
Positive News

See Recent GILD News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/20/2025BMO Capital Markets
4 of 5 stars
 Boost TargetOutperform$130.00 ➝ $135.00+9.93%
10/17/2025The Goldman Sachs Group
3 of 5 stars
 Boost TargetNeutral$105.00 ➝ $108.00-12.06%
10/9/2025Cantor Fitzgerald
4 of 5 stars
 Boost TargetOverweight$129.00 ➝ $135.00+14.16%
10/8/2025Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy (B)
10/8/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetSector Perform$98.00 ➝ $100.00-14.37%
10/8/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$125.00 ➝ $135.00+15.60%
9/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$135.00 ➝ $145.00+28.84%
9/12/2025Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$136.00 ➝ $143.00+27.53%
9/5/2025Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeModerate Buy
8/19/2025Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
8/19/2025Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralOutperform$128.00+8.48%
8/8/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$108.00 ➝ $112.00-6.78%
8/8/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$108.00 ➝ $127.00+15.16%
7/25/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$133.00+17.49%
4/25/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$130.00 ➝ $135.00+30.24%
4/25/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$132.00 ➝ $125.00+20.59%
3/5/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$116.00 ➝ $126.00+9.00%
3/5/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$120.00 ➝ $140.00+21.20%
2/18/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$80.00 ➝ $120.00+15.30%
2/13/2025DZ Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$108.00+4.54%
2/12/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$105.00 ➝ $110.00+6.33%
11/21/2024Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$90.00 ➝ $100.00+12.83%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$110.00+19.42%
11/8/2024Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$80.00 ➝ $95.00-2.30%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetEqual Weight$84.00 ➝ $95.00-1.72%
10/21/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/21/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeMarket PerformOutperform$74.00 ➝ $96.00+10.70%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$105.00+21.04%
8/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeMarket PerformOutperform$93.00+39.45%
4/26/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$90.00 ➝ $85.00+29.99%
4/24/2024HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeReduceHold$69.00+2.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:35 AM ET.


Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 15, 2025. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • The current stock price is around $114, which is near its 50-day moving average, indicating potential stability in the short term.
  • Gilead Sciences, Inc. reported a strong quarterly earnings per share (EPS) of $2.01, exceeding analysts' expectations, which reflects solid financial performance.
  • The company has a healthy net margin of 21.86%, suggesting effective cost management and profitability.
  • With a PEG ratio of 0.80, the stock may be undervalued relative to its growth rate, making it an attractive investment opportunity.
  • The recent upgrade by multiple analysts, including a "moderate buy" rating, indicates positive sentiment and potential for stock price appreciation.

Gilead Sciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • The debt-to-equity ratio of 1.13 suggests that the company has a relatively high level of debt compared to its equity, which could pose risks in a rising interest rate environment.
  • Despite a positive quarterly revenue growth of 1.4%, the overall growth may not be sufficient to meet long-term investor expectations.
  • The payout ratio of 62.95% indicates that a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
  • Analysts have set a consensus target price of $118.08, which may not provide substantial upside potential from the current stock price.
  • Market volatility, as indicated by a beta of 0.34, suggests that while the stock is less volatile than the market, it may still be subject to fluctuations that could impact investor returns.

GILD Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $120.04, with a high forecast of $145.00 and a low forecast of $95.00.

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 6 hold ratings, 20 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted downside of -2.49% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 5 upgrades by analysts.

Analysts like Gilead Sciences more than other "medical" companies. The consensus rating for Gilead Sciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how GILD compares to other companies.


This page (NASDAQ:GILD) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners